Animal data supports J&J's Alzheimer's vaccine

J&J's Alzheimer's research group at Janssen has found positive signs for bapineuzumab, its late-stage Alzheimer's therapeutic vaccine. In a study using mice, researchers found that those who were inoculated performed a simple task more effectively, which could mean the vax was successful at stopping amyloid plaque from binding with neurons. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.